Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results
30 avr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting
24 avr. 2013 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)
08 avr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference
22 mars 2013 16h12 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., March 22, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
26 févr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Cowen and Company 33rd...
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results
25 févr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
05 févr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 15th Annual BIO CEO &...
Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs
04 févr. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)
28 janv. 2013 07h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
02 janv. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 31st Annual J.P. Morgan...